JMAC vs. VALN, BGM, SYRE, NBTX, SANA, DNA, MNMD, BCAX, RLAY, and SEPN
Should you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Valneva (VALN), BGM Group (BGM), Spyre Therapeutics (SYRE), Nanobiotix (NBTX), Sana Biotechnology (SANA), Ginkgo Bioworks (DNA), Mind Medicine (MindMed) (MNMD), Bicara Therapeutics (BCAX), Relay Therapeutics (RLAY), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.
Maxpro Capital Acquisition vs. Its Competitors
Maxpro Capital Acquisition (NASDAQ:JMAC) and Valneva (NASDAQ:VALN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.
Valneva has a consensus price target of $15.00, indicating a potential upside of 36.12%. Given Valneva's stronger consensus rating and higher possible upside, analysts plainly believe Valneva is more favorable than Maxpro Capital Acquisition.
Maxpro Capital Acquisition has a net margin of 0.00% compared to Valneva's net margin of -33.87%. Maxpro Capital Acquisition's return on equity of 0.00% beat Valneva's return on equity.
Maxpro Capital Acquisition has higher earnings, but lower revenue than Valneva.
Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.
73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Valneva had 7 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 7 mentions for Valneva and 0 mentions for Maxpro Capital Acquisition. Valneva's average media sentiment score of 0.61 beat Maxpro Capital Acquisition's score of 0.00 indicating that Valneva is being referred to more favorably in the news media.
Summary
Valneva beats Maxpro Capital Acquisition on 7 of the 12 factors compared between the two stocks.
Get Maxpro Capital Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maxpro Capital Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:JMAC) was last updated on 10/6/2025 by MarketBeat.com Staff
